Cargando…

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

BACKGROUND: Discrepancies in genetic alterations found in melanoma are conspicuous between different ethnic groups. With the approval of BRAF- and MEK-targeted inhibitors in China, it is necessary to further elucidate the landscape of gene mutation in Chinese melanoma patients. METHODS: The frequenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Min, Zhang, Jing, Kong, Yunyi, Bai, Qianming, Qi, Peng, Zhang, Ling, Wang, Qian, Zhou, Xiaoyan, Chen, Yong, Zhu, Xiaoli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848432/ https://www.ncbi.nlm.nih.gov/pubmed/35282092 http://dx.doi.org/10.21037/atm-21-4235

Ejemplares similares

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
por: Moltara, Maja Ebert, et al.
Publicado: (2018)

BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study
por: Taskın, Orhun Cig, et al.
Publicado: (2023)

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
por: Zebary, A, et al.
Publicado: (2013)

Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population
por: Gutiérrez-Castañeda, Luz D., et al.
Publicado: (2020)

KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature
por: Chen, Feng, et al.
Publicado: (2018)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review
por: Gutiérrez-Castañeda, Luz Dary, et al.
Publicado: (2020)

Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas
por: Wróblewska, Joanna P., et al.
Publicado: (2021)

A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
por: Sun, Wei, et al.
Publicado: (2023)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
por: Tschandl, Philipp, et al.
Publicado: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma
por: Zablocka, Tatjana, et al.
Publicado: (2022)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
por: Vachtenheim, Jiri, et al.
Publicado: (2021)

Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status
por: Casadonte, Rita, et al.
Publicado: (2023)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia
por: Rinonce, Hanggoro Tri, et al.
Publicado: (2021)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
por: Shackelford, Rodney, et al.
Publicado: (2014)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
por: Heppt, Markus V., et al.
Publicado: (2017)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma
por: Conway, Caroline, et al.
Publicado: (2010)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis
por: Emelyanova, Marina, et al.
Publicado: (2017)

Functional RET G691S Polymorphism in Cutaneous Malignant Melanoma
por: Narita, N, et al.
Publicado: (2009)

Efficacy of Targeted Radionuclide Therapy Using [(131)I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
por: Akil, Hussein, et al.
Publicado: (2021)

Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer
por: Wu, Jing-Bo, et al.
Publicado: (2023)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

KRAS , NRAS , BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
por: Mirzapoor Abbasabadi, Zohreh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p0otqj2ae4qhn178o115lrpimc